New combo therapy shows promise for rare bleeding disorder

This study tests whether adding diammonium glycyrrhizinate (a liver-protecting compound) to standard high-dose dexamethasone can improve platelet counts in adults newly diagnosed with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. About 106 untreated patients with low platelets or bleeding symptoms will receive either the combination or dexamethasone alone. The main goals are to see if more patients achieve a safe platelet count at 14 days and maintain it for 6 months.